HFAI
@hfaimedia
Followers
57
Following
141
Media
12
Statuses
175
Heart Failure Association of India
Chennai
Joined August 2025
HFAI and HFA Scientific Statement on SGLT2i
SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI The reduction in HF events with SGLT2is in patients with CKD and T2DM further expanded their indication for the prevention of HF in these patients @JavedButler1
0
0
0
Chronic Kidney Disease Now in the Top 10 Causes of Death Worldwide
medpagetoday.com
CKD accounted for 1.48 million death globally in 2023
0
0
0
Long-Term Melatonin Use Associated to Increased Heart Failure Risk: Study
medicaldialogues.in
Scientists have uncovered troubling associations between the long-term use of melatonin supplements and increased risks of heart failure and mortality. A large-scale review analyzing health records...
0
0
0
LV diastolic revised 2025..simple algorithm
This is an important case for diastolic function assessment that was corrected in 2025 guideline. A main lesson is " Diastolic Function can be normal with reduced EF and/ or myocardial infarction." We should not adjudicate diastolic dysfunction based on clinical data. Always use
0
0
0
SGLT2i after UTI....
More on SGLT2 inhibitors and Urinary tract infections π SGLT2i after UTI in T2DM β safer than thought? π TriNetX US cohort Initiating SGLT2i within 3 months post-UTIvs DPP-4i β risk of: β’ Mortality β 41% lower (HR 0.59) β’ MAKE β 22% lower β’ Dialysis β 57% lower β’
0
0
0
π Even a few steps per day is beneficial! In 13,547 older women (mean age 72), walking β₯4,000 steps/day just 1β2 days/week lowered: πΉ All-cause mortality by 26% πΉ CVD risk by ~27% Walking β₯3 days/week cut mortality risk by 40%! More steps = greater benefit, but every bit
2
23
59
π₯ #DELIVER: Achieved Ejection Fraction and Effects of Dapagliflozin in #HeartFailure with Improved Ejection Fraction. #HFimpEF π In patients with #HFimpEF, the efficacy and safety of dapagliflozin in reducing #CV_death β οΈ or #worseningHF events were consistent irrespective of
3
27
53
UTI is uncommon with SGLT2i - mycotic infections are common
UTI is uncommon with SGLT2i - mycotic infections are common This study has important clinical implications β οΈ After UTI, 1 in 3 patients stopped SGLT2i Discontinuation led to higher CV & renal risk, with no reduction in recurrent UTIs. π‘ Following UTI - continue SGLT2i
0
0
0
Women derive more benefit from physical activity than men with respect to reduction of cardiovascular risk and related mortality, and can achieve protection at lower levels of engagement. From ~85,000 participants, open-access (blue=men) https://t.co/gfaPgCna4o
8
198
709
HFrEF and AF Rx
ποΈ π¨ #EuropeanJournalofHeartFailure consensus statement. Heart failure pharmacotherapy for pts with #HFrEF & concomitant #AtrialFibrillation: Review of evidence & call to action @escardio
@ESC_Journals @GiuseppeGalati_
@AmrAbdin10 @HanCardiomd
https://t.co/v279MHXpDL
0
0
0
T-TEER is safe and effective in selected patients with transvalvular CIED leads
Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR T-TEER is safe and effective in selected patients with transvalvular CIED leads. Effective TR reduction remains prognostically relevant, even in this
0
0
0
Role of Circadian Health in Cardiometabolic Health and Disease Risk https://t.co/krShIpV1VY
ahajournals.org
Cardiovascular and metabolic health are influenced by the circadian system, which regulates 24-hour rhythms across numerous physiologic processes. Disruptions to circadian rhythmicity can adversely...
0
9
29
Important question - should ischaemia LV dysfunction be revascularized ?
Revascularization in Ischemic Left Ventricular Dysfunction: a pathophysiology-guided, evidence-based approach Trials of routine coronary revascularization for iLVD have shown neutral results except for a benefit of CABG emerging beyond 5 years from surgery, supporting a
0
0
0
Diagnosing HFpEF (Heart Failure with Preserved Ejection Fraction)
2
117
548
Post-hoc analysis of SYNERGY-NASH trial reveals key insights on #tirzepatide in #MASH patients β
MASH resolution linked to greater weight loss (-16% vs -7%) β
Fibrosis improvement associated with better glycemic control β
Liver fat normalization was key mediator of both
0
28
85
π SGLT2i in the very elderly with heart failure Mean age 90 yrs! Mean Charlson Comorbidity Index score was 8.2 π Prospective multicentre study β’ β All-cause mortality: HR 0.67 β’ β HF rehospitalisation: HR 0.64 β’ β Composite outcome: HR 0.60 β
Benefits
7
49
143
Compared with targeting <140 mm Hg, targeting <120 mm Hg halved the risk of hemorrhagic #stroke and did not increase that of ischemic stroke. The stroke-preventing effect emerged after 1 year of intervention. Future studies are needed https://t.co/qB7ZmR2klb
#JACC
1
40
142
What's new in heart failure? September 2025 https://t.co/LVYGPpssmb
#EJHF @EJHFEiC @ESC_Journals #HeartFailure
0
70
213
Statin therapy during pregnancy. Read more in the @EHJ at https://t.co/DsdR8aBFMO
#PregnancyHealth #StatinTherapy #MaternalHealth #PregnancyCare @ESCardio @ESC_Journals
1
23
74
π Tips & Tricks in Beta-Blockers πΉ Nebivolol: most selective Ξ²1 β best for asthma/COPD πΉ Bisoprolol/Metoprolol: best rate control πΉ Nebivolol: lowest ED risk πΉ Carvedilol/Nebivolol: best BP effect π From my book: Tips and Tricks in Cardiology βοΈ Type βtipsβ if interested
22
121
460
Targets for LDL-C for each cardiovascular risk category Remember these numbers: 116, 100, 70, 55, 40 >>>> Low, moderate, high, very high, extreme risk ESC guidelines
6
101
384